Investing.com -- Abivax SA ADR (NASDAQ:ABVX) stock rose 1.8% Tuesday following renewed market speculation about potential takeover interest from pharmaceutical giants, despite company denials.
The latest uptick comes after French publication La Lettre reported that AstraZeneca (NASDAQ:AZN) is preparing a potential offer of €176 per share, valuing Abivax at approximately €13.75 billion. This follows a previous report from the same publication claiming Eli Lilly (NYSE:LLY) was considering a €15 billion offer for the company.
However, investors appear cautious about these reports, as Abivax shares remain well below levels that would indicate strong market confidence in an imminent acquisition. The credibility of the reports have come into question following quick market dismissals of previous stories.
Abivax Chief Executive Marc de Garidel recently addressed the takeover rumors in an interview with Reuters, dismissing them as "noise." He specifically refuted earlier reports about Eli Lilly’s interest, stating, "There was no discussion on the acquisition of Abivax... if there was a conversation, this would be illegal."
Both the French government and Abivax previously dismissed the December reports regarding Eli Lilly’s alleged talks with French authorities about acquiring the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.






















